en.Wedoany.com Reported - Jardine Matheson Holdings of Hong Kong, China, recently agreed to acquire I-MED Radiology Network, an Australian diagnostic imaging services provider, in a transaction with an enterprise value of A$3.4 billion, approximately US$2.4 billion.

This deal will allow Jardine Matheson to acquire full equity of I-MED from sellers including funds managed by private equity firm Permira and other existing shareholders. I-MED is a leading diagnostic imaging platform in Australia and New Zealand, operating 215 diagnostic imaging clinics across both countries, completing over 7 million patient examinations annually, and covering major imaging modalities such as MRI, CT, X-ray, ultrasound, and nuclear medicine. It also provides teleradiology services to the Australian, New Zealand, and U.S. markets through its I-TeleRAD business. The acquisition also includes I-MED's minority stake in Harrison.ai, which primarily develops medical imaging artificial intelligence tools, with applications including CT brain and chest scan analysis. For Jardine Matheson, I-MED provides a medical diagnostic entry point with established network scale, clinical resources, digital infrastructure, and regional market share. For I-MED, a new long-term capital shareholder will help it continue expanding its clinic network, teleradiology capabilities, and the application scope of AI imaging tools. Transaction funding will come from Jardine Matheson's balance sheet cash and debt financing, and remains subject to regulatory approvals and customary closing conditions, with completion expected in late 2026.

Since entering Permira's portfolio in 2018, I-MED has continuously expanded its presence in Australia, New Zealand, and the U.S. market, while upgrading around AI diagnostics, digital infrastructure, and clinical service efficiency.

Medical imaging is becoming a key direction for capital mergers and acquisitions in the healthcare sector. The growth in demand from an aging population, chronic disease screening, early cancer diagnosis, cardiovascular and cerebrovascular disease examinations, and preventive medicine will increase the frequency of imaging use within healthcare systems. The value of diagnostic imaging companies lies not only in the number of individual clinics but also in physician resources, equipment upgrade capabilities, data platforms, remote reading systems, appointment and referral efficiency, and the depth of AI tool integration. I-MED possesses a physical clinic network covering the Australian and New Zealand markets and extends its image interpretation capabilities to more medical institutions through its teleradiology business, giving it strong platform-like characteristics. As healthcare systems demand higher examination efficiency, image quality, and clinical workflow coordination, large diagnostic imaging platforms can improve service throughput and alleviate pressure on certain operational links through unified equipment procurement, centralized image reading, digital patient portals, and AI-assisted diagnostics. Jardine Matheson's previous business spanned real estate, retail, and automotive sectors. This entry into medical imaging assets indicates its capital allocation is shifting more towards healthcare infrastructure with stable cash flows, long-term demand growth, and regional expansion potential.

This medical imaging acquisition also reflects the attractiveness of healthcare service assets in Australia and New Zealand. I-MED operates in a market with a mature medical insurance payment system, high imaging examination penetration, and stable diagnosis and treatment demand. Regional leading platforms have entry barriers in terms of physician networks, equipment investment, and patient coverage. Post-transaction, I-MED will need to continue advancing in regulatory approvals, cross-market integration, compliant application of AI tools, and the pace of clinic network expansion. For the Asia-Pacific healthcare market, the combination of diagnostic imaging, teleradiology, and medical imaging AI is transforming medical service platforms from single offline examination providers into healthcare infrastructure assets with greater data, technology, and network synergy capabilities.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com